For the quarter, adjusted earnings per share came in at $1.63, topping analysts’ estimates. Revenue rose to $12.2 billion, also ahead of expectations, driven by stronger demand for newer treatments including Reblozyl, Camzyos and Breyanzi, the company said in a statement Thursday.
Shares were up 0.35% in premarket trading.
The Princeton, New Jersey-based drugmaker now expects 2025 sales of between $47.5 billion and $48 billion, lifting the low end of its range by $1 ...